BlackRock Fund Advisors’s Emergent Biosolutions EBS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$87.5M Buy
2,663,371
+372,992
+16% +$11.2M 0.02% 1307
2016
Q3
$72.2M Buy
2,290,379
+285,152
+14% +$8.29M 0.01% 1326
2016
Q2
$56.4M Buy
2,005,227
+114,715
+6% +$4.5M 0.01% 1406
2016
Q1
$68.7M Sell
1,890,512
-12,043
-0.6% -$425K 0.02% 1237
2015
Q4
$76.1M Buy
1,902,555
+107,633
+6% +$3.75M 0.02% 1179
2015
Q3
$51.1M Buy
1,794,922
+62,943
+4% +$2.07M 0.01% 1409
2015
Q2
$57.1M Buy
1,731,979
+32,165
+2% +$997K 0.01% 1434
2015
Q1
$48.9M Buy
1,699,814
+99,056
+6% +$2.84M 0.01% 1519
2014
Q4
$43.6M Buy
1,600,758
+149,456
+10% +$3.56M 0.01% 1549
2014
Q3
$30.9M Sell
1,451,302
-48,298
-3% -$1.11M 0.01% 1670
2014
Q2
$33.7M Sell
1,499,600
-36,113
-2% -$841K 0.01% 1672
2014
Q1
$38.8M Sell
1,535,713
-130
-0% -$3.28K 0.01% 1575
2013
Q4
$35.3M Buy
1,535,843
+45,430
+3% +$947K 0.01% 1633
2013
Q3
$28.4M Buy
1,490,413
+192,053
+15% +$3.43M 0.01% 1732
2013
Q2
$18.7M Buy
+1,298,360
New +$18.8M 0.01% 1899

Other funds holding EBS

BlackRock Fund Advisors's EBS Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Emergent Biosolutions (EBS) stake by 16% in Q4 2016, buying an estimated $11.2M and bringing the position to 2,663,371 shares worth $87.5M. The position accounts for 0.02% of the portfolio, ranked #1307.

BlackRock Fund Advisors first reported a position in EBS in Q2 2013 and has held it in 15 quarters since. 208 funds tracked by Wall St. Rank hold EBS as of Q4 2016.

  • BlackRock Fund Advisors held 2,663,371 shares of Emergent Biosolutions worth $87.5M as of Q4 2016.
  • BlackRock Fund Advisors bought 372,992 Emergent Biosolutions shares in Q4 2016, an estimated $11.2M.
  • Emergent Biosolutions made up 0.02% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1307 holding.
  • BlackRock Fund Advisors first reported a position in Emergent Biosolutions in Q2 2013 and has held it in 15 quarters since.
  • 208 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.